# Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

> **NCT00440947** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 515 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus I
- HIV Infection

## Interventions

- **DRUG:** Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
- **DRUG:** Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)

## Key facts

- **NCT ID:** NCT00440947
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2012-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440947, "Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00440947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*